Pharvaris (NASDAQ:PHVS) Hits New 12-Month High – Should You Buy?

Pharvaris N.V. (NASDAQ:PHVS)’s stock price hit a new 52-week high on Wednesday . The stock traded as high as $36.10 and last traded at $35.75, with a volume of 526211 shares changing hands. The stock had previously closed at $34.59.

Analyst Upgrades and Downgrades

Several research firms have commented on PHVS. HC Wainwright restated a “buy” rating on shares of Pharvaris in a research report on Tuesday, June 16th. Morgan Stanley boosted their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. UBS Group set a $74.00 price objective on Pharvaris in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Finally, Wedbush increased their price target on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.64.

Pharvaris Price Performance

The stock has a market cap of $2.34 billion, a P/E ratio of -11.24 and a beta of -2.34. The company has a fifty day moving average of $31.31 and a 200 day moving average of $28.49.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, analysts anticipate that Pharvaris N.V. will post -3.2 EPS for the current year.

Insider Activity

In other Pharvaris news, Director Robert Glassman sold 10,000 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $29.82, for a total value of $298,200.00. Following the sale, the director directly owned 10,500 shares in the company, valued at approximately $313,110. The trade was a 48.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Berndt Modig sold 23,333 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42. Following the completion of the sale, the chief executive officer directly owned 142,084 shares of the company’s stock, valued at $3,941,410.16. The trade was a 14.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 328,981 shares of company stock valued at $10,458,873 over the last quarter.

Institutional Trading of Pharvaris

A number of large investors have recently added to or reduced their stakes in PHVS. GF Fund Management CO. LTD. bought a new position in shares of Pharvaris in the fourth quarter valued at $35,000. JPMorgan Chase & Co. raised its position in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. Barclays PLC acquired a new stake in shares of Pharvaris during the fourth quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Pharvaris during the fourth quarter valued at $86,000. Finally, CoreCap Advisors LLC purchased a new stake in shares of Pharvaris during the second quarter valued at $93,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.